Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elamipretide in Primary Mitochondrial Myopathy (Phase 3, SC Daily, DBPC with Open-Label Extension)
2017-002447-15Phase 3Terminated
- Sponsor
- Stealth BioTherapeutics
- Start
- Feb 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in primary mitochondrial myopathies (PMM) and Mitochondrial myopathies (MM) comparing Elamipretide 40 mg SC with Placebo SC (2 arms). Primary endpoint: Primary efficacy endpoints (unspecified). Started Feb 2018; status: terminated.
02
Drugs
elamipretide
03
Conditions
primary mitochondrial myopathies (PMM)Mitochondrial myopathies (MM)
Beyond the preview
Go deeper on 2017-002447-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002447-15.